SynergyMed Devices is a medical device company focused on the development of cancer tumor treatment products based on an innovative noninvasive ablation technology. The company is registered in the US, based in Boston (with presence in Jerusalem), and is currently at the clinical stage. SynergyMed platform technology may be used as an alternative to surgery for the treatment of early-stage breast, head and neck, skin, and lung cancers for humans and also for the veterinary market. It may also be used for palliative care to relieve pain. The proven technology can locally ablate and destroy cancer tumors, precisely and effectively, without causing any damage to the surrounding healthy tissues. It is based on using specialized electromagnetic applicators which are placed around the region of interest. FDA approved nanoparticles are injected inside the tumor, which absorb the radiated electromagnetic energy efficiently, destroying the tumor without damaging the healthy tissue. The device is controlled through the company’s own developed algorithms which optimize the ablation process while precisely tracking temperature and measuring the administered treatment dose. The company has performed mice studies with breast cancer cell line, showing exceptional results, where the tumor disappeared within only a few days, leaving no scars or traces of cosmetic damage. It has also performed studies on superficial tumors in dogs with excellent results. SynergyMed Devices Inc. has an experienced team with backgrounds from leading corporate and academic institutions. The company is currently seeking funding and strategic partnerships.
